In Vivo Model Development for Usher Syndrome

Protheragen is dedicated to advancing preclinical research for Usher syndrome by offering a comprehensive suite of in vivo animal model development services. Our expertise in generating and characterizing mouse models with relevant genetic and phenotypic features enables researchers and pharmaceutical partners to accelerate the discovery and evaluation of novel therapeutics for this challenging genetic disorder.

Usher syndrome is the most common cause of combined deafness and blindness, resulting from mutations in various genes critical for sensory function. Robust animal models are essential for elucidating disease mechanisms and evaluating new treatments. At Protheragen, we utilize Mus musculus (mouse) as our primary species, leveraging a range of strains such as 129S6 x C57BL/6, 129SvJ, and SJL/J, as well as custom backgrounds. These models carry precise mutations in genes like Ush1c, Myo7a, Pcdh15, Oca2, and USH1C, closely recapitulating the human disease phenotypes. Our models are instrumental for translational research, enabling the validation of therapeutic strategies before clinical application.

Genetic Models

Genetic models are developed by introducing targeted mutations, knockouts, or knockins in genes implicated in Usher syndrome, such as Ush1c, Myo7a, Pcdh15, and USH1C. Techniques include CRISPR/Cas9 gene editing, transgenic expression, and conditional knockout strategies. These models faithfully mimic the genetic etiology and phenotypic spectrum of human Usher syndrome, including sensory deficits in hearing and vision. Advantages include high construct validity, reproducibility, and the ability to study gene-specific pathogenesis and therapeutic interventions. Primary applications are in mechanism-of-action studies, gene therapy evaluation, and long-term efficacy and safety assessments.

Chemically-Induced Models

Chemically-induced models are established by exposing animals to specific agents or environmental factors, such as light-induced retinal degeneration in genetically predisposed strains. For example, the 129SvJ strain with mutated Myo7a is subjected to controlled light exposure to accelerate retinal pathology. This approach enables rapid induction of disease features and is useful for studying gene-environment interactions. Advantages include the ability to modulate disease onset and severity, and to test interventions at various disease stages. These models are primarily used for screening protective agents, assessing environmental risk factors, and evaluating acute treatment responses.

Transgenic and Conditional Knockout Models

Transgenic and conditional knockout models employ sophisticated genetic engineering to control gene expression spatially and temporally. For instance, conditional knockout of Pcdh15 allows targeted gene disruption in specific tissues or developmental stages, while transgenic overexpression of mutated Ush1c enables the study of dominant-negative effects. The main advantages are flexibility in studying gene function, modeling complex inheritance patterns, and dissecting tissue-specific disease mechanisms. These models are valuable for investigating gene function, testing gene-editing therapies, and elucidating disease progression in a controlled manner.

Protheragen delivers an end-to-end solution for Usher syndrome model development, including model design, genetic engineering, phenotypic validation, and customized preclinical study execution. Our service encompasses breeding, genotyping, and comprehensive phenotyping (auditory brainstem response, electroretinography, vestibular function, and behavioral assays). Key efficacy endpoints include hearing thresholds, retinal structure and function, motor coordination, and molecular biomarker analysis. Our analytical capabilities cover histopathology, immunohistochemistry, in situ hybridization, and next-generation sequencing. Rigorous quality control is maintained through standardized protocols, genetic verification, and environmental monitoring to ensure data reliability and reproducibility.

Partnering with Protheragen gives you access to a robust platform of validated Usher syndrome models, expert scientific guidance, and tailored research solutions to accelerate your drug discovery pipeline. Our commitment to quality, innovation, and client collaboration ensures your preclinical studies are both efficient and impactful. Contact us today to discuss your project needs and discover how our in vivo model services can drive your Usher syndrome research forward.